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We have identified a gene encoding a homolog of vascular endothelial growth factor (VEGF) in the Pseudocowpox virus
(PCPV) genome. The predicted protein shows 27% amino acid identity to human VEGF-A. It also shows 41 and 61% amino acid
identity to VEGFs encoded by orf virus (ORFV) strains NZ2 and NZ7, respectively. Assays of the expressed VEGF-like protein
of PCPV (PCPVVR634VEGF) demonstrated that PCPVVR634VEGF is mitogenic for endothelial cells and is capable of inducing
vascular permeability. PCPVVR634VEGF bound VEGF receptor-2 (VEGFR-2) but did not bind VEGFR-1 or VEGFR-3. These results
indicate that PCPVVR634VEGF is a biologically active member of the VEGF family which shares with the ORFV-encoded VEGFs
a receptor binding profile that differs from those of all cellular members of the VEGF family. It seems likely that the biological
activities of PCPVVR634VEGF contribute to the proliferative and highly vascularized nature of PCPV lesions. © 2003 Elsevier
Science (USA)
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INTRODUCTION
Vascular endothelial growth factor (VEGF) is a mitogen
with specificity for endothelial cells and has the ability to
induce vascular permeability (Ferrara and Davis-Smyth,
1997; Senger et al., 1983). VEGF plays an important role
in vasculogenesis and angiogenesis during embryonic
development and in angiogenesis associated with a
number of pathological conditions including tumor for-
mation (Breier, 2000; Risau, 1997). The mammalian VEGF
family consists of five members, VEGF-A, VEGF-B,
VEGF-C, VEGF-D, and placental growth factor (PlGF). All
are secreted, homodimeric glycoproteins that share 30 to
45% amino acid identity (Stacker and Achen, 1999). They
exert their biological activities through a family of recep-
tor tyrosine kinases, VEGF receptor 1 (VEGFR-1) (Flt-1),
VEGFR-2 (Flk-1 or KDR), and VEGFR-3 (Flt-4) (Clauss,
2000). VEGF-A binds and activates both VEGFR-1 and
VEGFR-2 but not VEGFR-3, while PlGF and VEGF-B bind
only VEGFR-1. VEGF-C and VEGF-D bind both VEGFR-2
and VEGFR-3 but not VEGFR-1. The role of each recep-
tor–ligand interaction has yet to be defined precisely but
in general terms it appears that VEGFR-1 plays a role in
vascular endothelial differentiation and migration,
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genesis of endothelial cells, and VEGFR-3 is involved
in lymphangiogenesis (Robinson and Stringer, 2001;
Stacker et al., 2002). In addition to shared amino acid
sequences and functional characteristics, the VEGF fam-
ily members are also structurally similar. All members of
the VEGF family share a central domain referred to as
the VEGF homology domain (VHD), which contains a
cystine knot motif. (Achen et al., 1998; Joukov et al., 1997;
Muller et al., 1997b).
Pseudocowpox virus (PCPV) (synonym, paravaccinia
virus, milker’s nodule virus) is a member of the genus
Parapoxvirus, the type species of which is Orf virus
(ORFV) (Mercer et al., 1997; Robinson and Lyttle, 1992).
PCPV is maintained in cattle, while ORFV is maintained
in sheep and goats, but both viruses infect humans. The
clinical and histopathological features of PCPV lesions
are indistinguishable from those of ORFV lesions. They
both cause a contagious pustular dermatitis character-
ized by a progressive vesicle–pustule–scab formation in
their clinical course in animals and humans. There are
also some reports of extreme cases of human infection
by parapoxviruses in which giant tumor-like lesions are
described (Hunskaar, 1986; Pether et al., 1986; Rogers et
al., 1989; Savage and Black, 1972). The histological fea-
tures of PCPV and ORFV lesions include the endophytic
strand-like epidermal downgrowths (rete ridges), papil-
lary dermal edema, and marked capillary dilation andVEGF-E; vascular permeability factor; receptors, growth fa
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the VEGF family and this provided a probable explana-
tion for the proliferative and highly vascularized nature of
ORFV-infected lesions (Lyttle et al., 1994). ORFV is the
only virus which has been reported to encode such a
growth factor. It was noted that the predicted amino acid
sequences of VEGF-like proteins of ORFV strains, NZ2
and NZ7 (ORFVNZ2VEGF and ORFVNZ7VEGF, respectively),
are surprisingly different from each other, sharing only
45% identity (Lyttle et al., 1994). This is despite the fact
that the DNA sequences of other genes found in both
isolates are almost identical and the VEGF-like genes
occupy the same genomic location in both isolates. We
and others recently showed that the ORFV VEGFs share
some of the functional features of mammalian VEGF
(Meyer et al., 1999; Ogawa et al., 1998; Wise et al., 1999).
Purified viral VEGFs were shown to stimulate the prolif-
eration of vascular endothelial cells, to promote vascular
permeability, and to bind VEGFR-2 and neuropilin-1, but
not VEGFR-1 or VEGFR-3. This receptor binding profile is
unique among the mammalian VEGF family, suggesting
that the viral VEGFs constitute a new group within the
family. We have constructed a recombinant ORFV in
which the VEGF-like gene was disrupted and used this to
demonstrate ORFVNZ2VEGF function in vivo. During infec-
tion of sheep, the absence of an intact viral VEGF gene
was associated with lesions that lacked the striking
dermal vascularization and marked epidermal prolifera-
tion seen in wild-type virus infections (Savory et al.,
2000).
Numerous poxviruses have been shown to have
genes which encode factors that determine virulence,
pathogenesis, and host range (Alcami et al., 1998;
Spriggs, 1996). Such genes, including the ORFV VEGF
genes, are frequently located in the termini of the ge-
nome. The similar histological features of PCPV and
ORFV lesions suggested that PCPV might also encode a
VEGF-like molecule and we hypothesized that such a
gene might differ substantially in DNA sequence from the
ORFV VEGFs, but occur in a similar genomic location. In
this study, we identified a gene encoding a homolog of
VEGF in the right terminus of the PCPV genome and
conducted functional analysis of the expressed and pu-
rified protein.
RESULTS
Identification of a VEGF-like gene in PCPV
The published map of EcoRI digestion sites of PCPV
strain VR634 includes an 18-kb fragment (EcoRI C) at the
right genome terminus (Gassmann et al., 1985; Robinson
et al., 1987). This EcoRI fragment occupies a genomic
location similar to that of the VEGF gene of ORFVs (Fig.
1). Within PCPV EcoRI C we mapped three BamHI sites
(expanded in Fig. 1) and analysis of the DNA sequences
adjacent to one of these BamHI sites revealed evidence
of a VEGF-like gene. The DNA sequence of this gene and
the flanking regions was determined and is shown in Fig.
2, where it is aligned with the related sequences of ORFV
strains NZ2 and NZ7.
Analysis of this region of PCPV DNA revealed that, in
common with the ORFV sequences, it contains the partial
sequence of a homolog of the vaccinia virus F9L gene,
FIG. 1. Restriction enzyme cleavage maps of genomic DNA of PCPV strain VR634 and ORFV strains NZ2 and NZ7. Cleavage sites for EcoRI are
marked by vertical bars extending above the map and HindIII sites by bars extending below. An 18-kb fragment (EcoRI C) is expanded and BamHI
sites are shown. Shaded bars indicate the locations of the VEGF-like genes.
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FIG. 2. Alignments of DNA sequences of the VEGF-like genes and flanking regions of PCPV and ORFV strains NZ7 and NZ2. DNA alignments of
the VEGF-like genes were determined based on deduced amino acid sequences as aligned in Fig. 3. Nucleotides identical to the PCPV sequence
are indicated by dots. Start codons and stop codons are shown in bold letters. Putative early promoter sequences are shaded and early transcriptional
termination motifs are underlined. The ITR junctions of NZ7 and NZ2 are indicated.
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the complete sequence of a VEGF-like gene, and the
partial sequence of a homolog of the ORF3 gene of NZ2
(Fleming et al., 1991; Fraser et al., 1990). The DNA se-
quence of the F9L-like gene and the ORF3-like gene of
PCPV are very similar to ORFV sequences except within
the last 40 bp of the F9L-like gene.
The noncoding region following the stop codon of the
F9L-like gene is A  T-rich in all three parapoxviruses
but the sequences are not well conserved except for an
early promoter-like sequence (shaded box in Fig. 2) for
the VEGF gene. This early promoter-like sequence of
PCPV is identical with that of NZ7, while NZ2 has 2-bp
mismatches with the others. An early transcriptional ter-
mination sequence (TTTTTNT, underlined in Fig. 2)
(Fleming et al., 1991) follows the stop codon of the VEGF
gene in all three viruses. Early transcriptional control
motifs identified in Vaccinia virus (Cochran et al., 1985;
Weir and Moss, 1987) are conserved in ORFV (Fleming et
al., 1991) and also appear to be a feature of PCPV.
The VEGF gene sequences of the three viruses share
only 47 to 65% nucleotide sequence identity (Table 1).
The PCPV VEGF gene has a G  C content of only 39%
despite the high G  C content of the whole genome
(63%, Wittek et al., 1979). This feature is also seen in the
NZ7 VEGF gene but is less apparent in the NZ2 VEGF
gene. Alignment of the viral VEGF genes with human
VEGF-A (isoform 121) nucleotide sequence revealed only
a low level of sequence identity (Table 1). The sequences
between the stop codon of the VEGF gene and the start
codon of the ORF3 (-like) gene in PCPV, NZ7, and NZ2
share a relatively A  T-rich content but differ in length
(Fig. 2).
VEGF amino acid sequence comparisons
The coding region of the PCPV VEGF is 4 to 19 codons
longer than those of the ORFV VEGFs, largely as a result
of a serine-rich domain in the N-terminus of the mature
peptide. In common with the ORFV VEGFs, the VEGF
encoded by PCPV strain VR634 (PCPVVR634VEGF) in-
cludes a potential signal sequence as predicted by Sig-
nalP V2.0 (Nielsen et al., 1997), an N-linked glycosylation
site (Asn103–Thr105) and a threonine/proline-rich C-ter-
minus that contains potential O-linked glycosylation sites
(Thr140–Ser141, Thr144–Thr148) as predicted by NetO-
Glyc 2.0 (Hansen et al., 1997). This program predicts
further O-linked glycosylation sites that were not seen in
ORFVNZ2VEGF (Fig. 3).
Members of the VEGF family share a VHD containing
eight cysteine residues that form a cystine knot motif and
link the subunits of the antiparallel homodimer. All eight
cysteines are conserved in PCPVVR634VEGF and in the
ORFV VEGFs. The predicted amino acid sequence of
PCPV VEGF was compared with the 121-amino-acid iso-
form human VEGF-A and the VHD of the other members
TABLE 1
VEGF Sequence Comparisons
PCPV NZ7 NZ2 VEGF-A
PCPV — 60.8 41.4 27.2
NZ7 65.1 — 45.1 24.5
NZ2 47.3 47.5 — 35.3
VEGF-A 38.5 34.9 46.0 —
Note. The percentages of amino acid sequence identities (above the
diagonal) were calculated from the full length of the molecules as
aligned in Fig. 3. Percentages of nucleotide sequence identities (below
the diagonal) were calculated from DNA alignments based on the
amino acid alignments shown in Fig. 3. VEGF-A is human isoform 121
(GenBank Accession Nos. AF214570 and AAF19659 for DNA and amino
acid sequences, respectively).
FIG. 2—Continued
301THE VEGF-LIKE GENE OF Pseudocowpox virus
of human VEGF family as well as ORFV VEGFs (Fig. 3
and Table 1). The PCPV VEGF gene encodes a predicted
peptide with 61 and 41% sequence identity to
ORFVNZ7VEGF and ORFVNZ2VEGF, respectively. The amino
acid sequence identity of PCPVVR634VEGF to VEGF-A
(27%) is similar to that of the ORFV VEGFs. If the com-
parison is limited to the VHDs of viral and human VEGFs,
then PCPVVR634VEGF has 62, 44, 34, 35, 32, 32, and 31%
sequence identities to ORFVNZ7VEGF, ORFVNZ2VEGF,
VEGF-A, -B, -C, and -D, and PlGF, respectively.
Expression and purification of PCPVVR634VEGF
To determine the function of PCPVVR634VEGF, the coding
region of the gene was cloned into a eukaryotic expression
vector such that the expressed product would include the
FLAG octapeptide at the C-terminus. The fusion protein
was expressed in 293-EBNA cells and was purified by
affinity chromatography with anti-FLAG M2 resin followed
by elution with FLAG peptide. Analysis of this material by
SDS–PAGE and silver staining (Fig. 4A) or Western blotting
(Fig. 4B) demonstrated under nonreducing conditions a
band of48–52 kDa, whereas under reducing conditions a
faster migrating band of28–30 kDa was seen. The bands
detected are consistent with PCPVVR634VEGF being a disul-
fide-linked homodimer with a monomeric molecular mass
of 29 kDa. This is larger than the predicted size of 15.0
kDa and is likely to be the result of N- and O-linked glyco-
sylation at sites described above. To examine the glycosyl-
FIG. 3. Comparison of viral VEGFs with other members of the VEGF family. The deduced amino acid sequences of viral VEGFs were aligned with
human VEGF-A (isoform 121) (GenBank Accession No. AAF19659) and the VHD of human VEGF-B (AAC50721), human VEGF-C (P49767), human
VEGF-D (O43915), and human PlGF (CAA38698). Residues showing identity to PCPVVR634VEGF are indicated by dots. Conserved cysteine residues of
the cystine knot motif are indicated with asterisks. The predicted signal sequence of PCPVVR634VEGF is indicated by a line above the sequence. The
potential sites of N- and O-linked glycosylation of PCPVVR634VEGF are indicated by italicized N and O, respectively. Asn88 of VEGF-A (indicated by a
“#” symbol above the aligned sequences) is an accessible residue on the receptor binding face of VEGF-A (see Discussion).
FIG. 4. Analysis of purified PCPVVR634VEGF. The purified protein was resolved by SDS–PAGE and identified by (A) silver staining and (B) Western
blotting with anti-FLAG monoclonal antibody. Molecular weight markers are indicated. R and NR show samples under reduced and nonreduced
conditions, respectively. (C) Enzymatic removal of the N- and O-linked sugars. Purified PCPVVR634VEGF was reduced by boiling in the presence of
2-mercaptoethanol and was then treated with the indicated combination of enzymes. The proteins were resolved by SDS–PAGE and visualized by
silver staining.
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ation state of PCPVVR634VEGF, purified protein was deglyco-
sylated by enzymatic removal of the N- and O-linked sug-
ars. Following enzymatic treatment the proteins were
resolved by SDS–PAGE and visualized by silver staining
(Fig. 4C). Treatment with N-glycosidase F reduced the mo-
nomeric size of PCPVVR634VEGF by 2 kDa. The combined
treatment of N-glycosidase F, sialidase, and O-glycosidase
further reduced the monomeric size of PCPVVR634VEGF by
4 kDa. The monomeric mass of 23 kDa observed for
deglycosylated PCPVVR634VEGF remains larger than the pre-
dicted size. This residual size difference may be due to
incomplete enzymatic removal of the N- and O-linked sug-
ars or the protein may not be resolved predictably by SDS–
PAGE. A non-FLAG-tagged protein that comigrated with the
nonreduced form of PCPVVR634VEGF was also detected by
silver staining and was determined to be BSA derived from
the fetal calf serum (FCS) used to supplement the culture
medium (data not shown). Control preparations containing
this protein but lacking PCPVVR634VEGF had no activity in the
VEGF assays described below (data not shown; Savory et
al., 2000; Wise et al., 1999).
PCPVVR634VEGF binds to soluble VEGFR-2 extracellular
domains
To investigate the interactions between PCPVVR634VEGF
and the VEGFRs, PCPVVR634VEGF was tested for its ability to
bind to soluble Ig fusion proteins containing the extracellu-
lar domains of human VEGFR-1 or VEGFR-2. The Ig fusion
proteins were expressed in 293-EBNA cells, precipitated
from conditioned medium with protein A–Sepharose, and
incubated with metabolically labeled FLAG-tagged
PCPVVR634VEGF or FLAG-tagged mouse VEGF-A. Labeled
proteins bound to the Ig fusion proteins were analyzed by
SDS–PAGE and detected using a PhosphoImager (Fig. 5).
Polypeptides corresponding to the size of PCPVVR634VEGF
and mouse VEGF-A were precipitated by VEGFR-2-Ig. In
contrast, VEGFR-1-Ig precipitated only VEGF-A. No labeled
protein was precipitated from the medium of cells trans-
fected with the expression vector lacking sequence encod-
ing VEGF (data not shown). PCPVVR634VEGF was also
shown to be unable to bind human VEGFR-3-Ig in a similar
assay (data not shown). These data confirm that
PCPVVR634VEGF can bind to VEGFR-2 but does not bind
VEGFR-1 or VEGFR-3.
PCPVVR634VEGF binds and cross-links VEGFR-2
PCPVVR634VEGF was tested in a bioassay that detects
ligands for VEGFR-2 (Fig. 6). The bioassay makes use of
Ba/F3 cells in which activation of a chimeric receptor con-
sisting of the extracellular domain of mouse VEGFR-2 and
the transmembrane and cytoplasmic domains of the EpoR
rescues cells from their dependence on IL-3, allowing the
cells to proliferate in the absence of IL-3. VEGF-A, VEGF-C,
VEGF-D, and ORFVNZ2VEGF, which are ligands for VEGFR-2,
all stimulate growth of this cell line in a specific and
dose-dependent fashion (Achen et al., 1998; Makinen et al.,
2001; Stacker et al., 1999; Wise et al., 1999). Purified
PCPVVR634VEGF was able to induce detectable DNA synthe-
sis in the bioassay cell line from a concentration of 25
ng/ml, whereas mouse VEGF-A was able to induce detect-
able DNA synthesis from a concentration of 5 ng/ml. Over-
all, PCPVVR634VEGF was about fourfold less potent in the
FIG. 5. The VEGFR binding specificity of PCPVVR634VEGF. Soluble
fusion proteins consisting of the extracellular domains of VEGFRs and
the Fc portion of human IgG1 were used to assess the receptor binding
specificity of PCPVVR634VEGF. Biosynthetically labeled conditioned me-
dium derived from 293-EBNA cells transfected with a plasmid encoding
FLAG-tagged PCPVVR634VEGF or mouse VEGF-A (isoform 164) was
mixed either with anti-FLAG M2-agarose (M2) or with VEGFR-1-Ig (R1)
or VEGFR-2-Ig (R2) bound to protein A–Sepharose. Immunoprecipitated
proteins were resolved by SDS–PAGE and visualized by PhosphoIm-
ager analysis.
FIG. 6. PCPVVR634VEGF binds and cross-links VEGFR-2 in a VEGFR-
2-specific bioassay. Purified proteins were tested for their ability to
induce proliferation of Ba/F3 cells expressing a chimeric receptor
consisting of the extracellular domain of mouse VEGFR-2 and the
transmembrane and cytoplasmic domains of EpoR. Ba/F3 cells were
washed with medium free of IL-3 and incubated in medium containing
dilutions of PCPVVR634VEGF, mouse VEGF-A, or control medium for 48 h
at 37°C. DNA synthesis was quantitated by [3H]thymidine incorporation
and beta counting. Values are expressed as the mean  SD of two
replicate wells and are representative of four experiments.
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bioassay than VEGF-A. This reduced level of activity is
similar to that reported for ORFVNZ2VEGF, VEGF-C, and
VEGF-D (Makinen et al., 2001). These results clearly dem-
onstrate that PCPVVR634VEGF can bind to and cross-link the
extracellular domains of VEGFR-2 and thereby has the
potential to induce a proliferative response.
PCPVVR634VEGF is mitogenic for endothelial cells
Members of the VEGF family of molecules show variable
degrees of mitogenicity for endothelial cells. The mitogenic
capacity of PCPVVR634VEGF was tested using human micro-
vascular endothelial cells (HMVECs). The cells were ex-
posed to purified growth factors for 3 days before being
assessed for growth. PCPVVR634VEGF and mouse VEGF-A
were able to stimulate an equivalent increase in the num-
ber of cells after 3 days compared with medium that did not
contain added growth factors (Fig. 7). An analysis of vari-
ance (two-factor ANOVA with replication) did not reveal a
statistically significant difference (P  0.05) between the
responses to PCPVVR634VEGF and VEGF-A, indicating that
PCPVVR634VEGF was able to induce proliferation in HMVECs
with a potency equivalent to that of VEGF-A.
PCPVVR634VEGF induces vascular permeability
Members of the VEGF family of molecules also show
varying abilities to induce vascular permeability. The
ability of PCPVVR634VEGF to induce vascular permeability
was tested in the Miles assay. Guinea pigs were injected
intradermally with various concentrations of the purified
growth factors PCPVVR634VEGF and mouse VEGF-A. In
comparison to buffer alone, there was detectable and
dose-dependent permeability induced by PCPVVR634VEGF
and VEGF-A (Fig. 8). PCPVVR634VEGF, however, is consid-
erably less potent as a vascular permeability factor than
VEGF-A.
DISCUSSION
We determined the DNA sequence of 2.5 kb of the
PCPV genome and within this region identified a VEGF-
like gene. Purified PCPVVR634VEGF was found to be a
glycosylated disulfide-linked homodimer with a mono-
meric subunit of 29 kDa on SDS–PAGE. The VEGFR-2
bioassay using Ba/F3 cells expressing the extracellular
ligand binding domain of VEGFR-2 revealed that
PCPVVR634VEGF is able to bind and cross-link VEGFR-2.
As expected from these results, PCPVVR634VEGF showed
mitogenic activity on HMVECs. It also induced vascular
permeability in the Miles assay. In addition we also
found that PCPVVR634VEGF, like VEGFs encoded by ORFV,
did not bind VEGFR-1 or VEGFR-3 (Meyer et al., 1999;
Ogawa et al., 1998; Wise et al., 1999). The discovery that
both PCPV and ORFV encode VEGF-like factors is con-
sistent with the observed histopathological similarities in
PCPV and ORFV lesions. We have recently demonstrated
that ORFVNZ2VEGF is responsible for a marked angio-
genic response in ORFV-infected lesions by using a
recombinant virus in which the VEGF-like gene was dis-
rupted (Savory et al., 2000). It therefore seems likely that
the biological activities of PCPVVR634VEGF also contribute
to the proliferative and highly vascularized nature of
PCPV lesions.
FIG. 7. Mitogenic activity of PCPVVR634VEGF on HMVECs. HMVECs
were cultured with dilutions of PCPVVR634VEGF and mouse VEGF-A. Cell
proliferation induced by purified proteins was quantitated by counting
of cells after 72 h. Values are expressed as a proliferation index, which
is the mean increase in cell number in four replicate wells divided by
the mean background cell number in four wells which lacked purified
protein. Error bars indicate 1 SD.
FIG. 8. Vascular permeability induced by PCPVVR634VEGF in the Miles
assay. Anesthetized guinea pigs were given intracardiac injections of
Evans blue dye. Purified proteins were injected intradermally to shaved
areas of the animals’ backs. After 30 min, animals were sacrificed and
the appropriate area of skin was excised. Samples were eluted in
formamide and the absorbance reading at 620 nm was recorded.
Values are expressed as the mean of two replicate injection sites and
are representative of three experiments. Error bars indicate 1 SD of the
mean.
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Despite these functional similarities with the ORFV
VEGFs, PCPVVR634VEGF is also clearly divergent in se-
quence from both of the two major variants of VEGF
encoded by strains of ORFV. The predicted amino acid
sequence of PCPVVR634VEGF has only 61 and 41% identity
to those of ORFVNZ7VEGF and ORFVNZ2VEGF, respectively.
These values are lower than generally reported between
paired genes from the same genus of poxviruses (Mer-
cer et al., 2002).
The unusually high sequence variation between the
PCPV VEGF and the ORFV VEGFs is mirrored in the
ORFV VEGFs, with up to 31% amino acid sequence di-
vergence among NZ2-like VEGFs (Mercer et al., 2002)
and even greater divergence between the NZ2 and NZ7
VEGFs. The source of this extensive sequence variation
is unclear. A number of possible explanations can be
considered, although in no case do they seem fully
satisfactory and they must be considered speculative.
One possible explanation of the variation between the
viral VEGFs is that the major variants are derived from
different members of the mammalian VEGF family, per-
haps including members that have yet to be identified.
Another possible explanation of the pronounced varia-
tion between the NZ2 and NZ7 VEGF sequences is
raised by our analysis of the VEGF encoded by PCPV.
The sequence relatedness between PCPVVR634VEGF and
ORFVNZ7VEGF is greater than that between ORFVNZ2VEGF
and ORFVNZ7VEGF (Table 1). This is true not only of the
VEGF open reading frame but also of the immediately
adjacent sequences (Fig. 2). It is only in sequences more
distant from the VEGF genes that the expected close
relationship between NZ2 and NZ7 become apparent
(Fig. 2). This raises the possibility that strain NZ7 is a
natural recombinant between strains of ORFV and PCPV
and that the segment of DNA spanning the VEGF gene of
strain NZ7 is derived from PCPV. The overlapping host
ranges of parapoxviruses (Inoshima et al., 2001; Robin-
son and Lyttle, 1992) could provide an opportunity for
such recombination and a precedent for interspecies
recombination among poxviruses is provided by Malig-
nant rabbit fibroma virus, which is believed to have
arisen by genetic recombination between Shope fibroma
virus andMyxoma virus (Block et al., 1985). However, this
explanation too is not fully satisfactory in that the nucle-
otide sequence identity between the PCPV and NZ7
VEGF genes (65%) is substantially less than that between
the most divergent pair of NZ2-like ORFV VEGF genes
(76%) (Mercer et al., 2002) and so demands even greater
sequence divergence between the VEGF genes of PCPV
isolates than is seen between ORFV isolates. Another
species of parapoxvirus might be an alternative source
of the NZ7 VEGF gene but VEGF genes have not been
detected in other species, such as Bovine papular sto-
matitis virus (Bu¨ttner and Rziha, 2002).
Alignments of the viral VEGFs with full-length versions
of members of the VEGF family reveal somewhat greater
similarity to VEGF-A than to other groups of the family.
However, the extent of sequence divergence seen in
these alignments is not consistent with the viral VEGFs
being a subgroup of the VEGF-A group. If the compari-
sons are restricted to the VHDs of representatives of the
VEGF family groups, then PCPVVR634VEGF shows a very
narrow spread of amino acid sequence identity (31 to
35%), with little evidence that it is more closely related to
any one of the family groups. These observations indi-
cate that the viral VEGFs form a separate group within
the VEGF family. This classification is supported by the
phylogenetic analysis shown in Fig. 9, which illustrates
the clear separation of the viral VEGFs from other groups
of the VEGF family. The phylogenetic tree also illustrates
both the extent of sequence divergence within the viral
VEGF group and the closer relationship of ORFVNZ7VEGF
to PCPVVR634VEGF than to ORFVNZ2VEGF.
Studies of VEGF structure and function have identified
FIG. 9. Phylogenetic trees of viral VEGFs and other members of the
VEGF family based on amino acid sequences of the VHD. Sequences
used for the analysis are the viral VEGFs and the human VEGFs shown
in Fig. 3 as well as VEGF-A of cow (AAA30502), sheep (CAA61677),
mouse (AAB22254), and chicken (BAA24925), VEGF-B of cow
(BAA77686) and mouse (AAC52823), VEGF-C of cow (BAA77687),
mouse (P97953), and quail (CAA75799), VEGF-D of mouse (P97946) and
chicken (AAM12733), and PlGF of cow (BAA77684) and mouse
(CAA56453). The sequences were aligned manually and the genetic
distance for each pair was estimated using the program EprotDist
based on Dayhoff PAM matrix. Resulting distance matrix data were
used to estimate phylogenies by the program Ekitsch by the Fitch–
Margoliash method. Phylogenetic trees were visualized by TreeView-
PPC Ver1.6.6 (Page, 1996) on Apple Macintosh.
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receptor binding domains and have implicated specific
residues in mediating binding to the VEGF receptors
(Keyt et al., 1996; Li et al., 2000; Muller et al., 1997;
Wiesmann et al., 1997). Our comparisons of ORFV VEGF
variants and members of the mammalian VEGF family
revealed only limited correlations between conserved
residues and the ability to recognize specific VEGF re-
ceptors (Mercer et al., 2002). A strong correlation is
apparent between binding of VEGFR-2 and the presence
of an Asn residue at a position equivalent to Asn88 of
human VEGF-A (shown by a “#” symbol in Fig. 3). This
residue is conserved in PCPVVR634VEGF (Asn90, Fig. 3).
Crystal structure determination of human VEGF-A has
shown that Asn88 is an accessible residue on the
VEGFR-2 binding face of VEGF-A (Muller et al., 1997a).
Structural modeling of the ORFV VEGFs has allowed
us to propose a possible basis for the inability of these
VEGFs to bind VEGFR-1 (Mercer et al., 2002). The struc-
ture determined by X-ray crystallography for the human
VEGF-A homodimer revealed a groove at each end of the
dimer that is postulated to play a role in its binding to
VEGFR-1 (Wiesmann et al., 1997). Our models of ORFV
VEGFs suggest that this groove is blocked in the ORFV
VEGFs and this may therefore contribute to their inability
to bind VEGFR-1. Modeling of PCPVVR634VEGF indicated
that, consistent with its inability to bind VEGFR-1, it too is
unlikely to have a groove able to assist in binding
VEGFR-1 (data not shown). Structural determinations in
conjunction with site-directed mutagenesis and receptor
binding assays will be required to assess the validity of
these models.
Our analysis of 2.5 kb of PCPV DNA sequence con-
firms the classification of PCPV as a member of the
Parapoxvirus genus but as a species separate from
ORFV. The PCPV sequence revealed evidence of three
genes, all of which have significant sequence related-
ness to genes of ORFV. Furthermore, these genes occur
in the same order and orientation in both viruses, they
occupy similar genomic locations, and two of the genes
have not been reported in other poxviruses. These ob-
servations support the inclusion of PCPV and ORFV in
the same genus, whereas a comparison of the PCPV
sequence of a F9 homolog and the ORF-3-like gene with
two ORFV isolates validates the separation of PCPV and
ORFV as two species. Our data therefore support the
conclusions of the only previous report of DNA sequence
of PCPV (Inoshima et al., 2001).
The identification of PCPVVR634VEGF as another major
subgroup within the viral VEGFs will provide opportuni-
ties to compare the structural and functional character-
istics of these factors with their mammalian counter-
parts. Such comparisons are likely to be useful in iden-
tifying elements of these growth factors that mediate
their interactions with the family of VEGF receptors and
mediate their wide range of biological activities.
MATERIALS AND METHODS
Cells and viruses
Primary bovine testis (BT) cells were grown in Eagle’s
minimal essential medium containing 10% FCS and 5%
lactalbumin hydrolysate. PCPV strain VR634 (Gassmann
et al., 1985) was propagated in BT cells as described
previously (Robinson et al., 1982).
Purification of virus and DNA extraction
Viral particles propagated in BT cells were purified in
sodium diatrizoate gradients as described previously
(Robinson et al., 1982). Purified virions were treated with
proteinase K and SDS followed by isolation of viral DNA
in guanidine HCl–CsCl gradients as described previ-
ously (Mercer et al., 1987).
DNA cloning and sequence analysis
The general methods used have been described pre-
viously (Fraser et al., 1990). Double-stranded DNA tem-
plates were prepared and sequenced by procedures
recommended by Applied Biosystems Inc. (ABI). Re-
agents used for sequencing were supplied by ABI, and
the products of sequencing reactions were analyzed with
an ABI Model 377 sequencing system. The nucleotide
sequences of both strands of the region under study
were determined and were assembled using the pro-
gram SeqManII Ver. 5.00 (DNASTAR, Inc.). Nucleotide
and predicted amino acid sequences were compared
with database sequences using the BLAST suite of pro-
grams (http://www.ncbi.nlm.nih.gov/BLAST/).
Expression of the VEGF-like gene
The PCPV VEGF-like gene was expressed as a fusion
protein using a derivative of the mammalian expression
vector pEF-BOS (Mizushima and Nagata, 1990). A DNA
fragment containing the VEGF-like gene was amplified
by PCR using virus DNA as template with two primers:
GF5-FLAG (5-AGCGCCCGGCGCGCCAGAAGTTGATA-
ACTACGT-3, AscI site underlined) and GF6-FLAG (5-
ACTCGAACGCGTTCTAGGTTCTTTTGTT-3, MluI site un-
derlined). The PCR product was digested with AscI and
MluI and inserted into the pEF-BOS-I-FLAG expression
vector (kindly provided by Clare MacFarlane, Walter and
Eliza Hall Institute of Medical Research, Melbourne, Aus-
tralia) at the AscI site, immediately upstream of the DNA
sequence encoding the FLAG octapeptide (IBI/Kodak),
so that the FLAG octapeptide would be fused to the
C-terminus of the synthesized VEGF-like peptide and this
fusion protein would be secreted from transfected cells
(Wise et al., 1999). This plasmid was transfected into
293-EBNA cells using FuGENE6 (Roche) as recom-
mended by the manufacturer. After 7 days of incubation,
conditioned cell culture medium was collected and clar-
ified by centrifugation before FLAG-tagged proteins were
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recovered by affinity chromatography using anti-FLAG
M2-agarose (Sigma). Alternatively, an expression cas-
sette was excised from the above plasmid and inserted
into the expression vector pAPEX-3 (Evans et al., 1995)
(kindly provided by Steven Squinto, Alexion Pharmaceu-
ticals, New Haven, CT) to allow stable expression of the
VEGF-FLAG fusion protein and the protein was purified
from conditioned medium. Non-FLAG-tagged mouse
VEGF-A (isoform 164) was expressed in CHO cells and
purified (Stacker et al., 1999). Mouse VEGF-A (isoform
164) was also expressed in the form of a fusion protein
with the FLAG peptide using an pAPEX-3-derived vector
as described above for PCPVVR634VEGF. This protein was
used in binding assays utilizing soluble VEGFR extracel-
lular domains (see below).
SDS–PAGE and immunoblotting
Purified PCPVVR634VEGF was boiled in the SDS sample
buffer with or without 2-mercaptoethanol and resolved by
SDS–PAGE (Laemmli, 1970). The protein was transferred
to nitrocellulose membrane and HRP-conjugated anti-
FLAG M2 monoclonal antibody (Sigma) was used to
detect the FLAG-tagged protein (Achen et al., 1998).
Deglycosylation of PCPVVR634VEGF
Purified protein (0.6 g) was diluted in 0.05 M sodium
phosphate (pH 7) containing 0.1% SDS and 20 mM 2-mer-
captoethanol and boiled for 5 min. The mixture was
cooled on ice and Tween 20 was added to 0.75%. Five
units of N-glycosidase F (Roche), 5 mU of sialidase
(Neuraminidase, Roche), or 1.25 mU of O-glycosidase
(Roche) was added in the following combinations: N-
glycosidase F alone, N-glycosidase F and sialidase, or
N-glycosidase F, sialidase, and O-glycosidase. Alterna-
tively no enzyme was added. The mixtures were then
incubated at 37°C for 3 h. The proteins were resolved by
SDS–PAGE and visualized by silver staining.
Binding assays with soluble VEGFR extracellular
domains
The details of these assays have been described else-
where (Wise et al., 1999). Briefly, 293-EBNA cells were
transfected with plasmids encoding the soluble human
receptor–Ig fusion proteins VEGFR-1-Ig or VEGFR-2-Ig.
The soluble fusion proteins were precipitated from the
conditioned medium using protein A–Sepharose beads.
Beads were then combined with conditioned medium
from 293-EBNA cells that had been transfected with
expression plasmids encoding PCPVVR634VEGF or mouse
VEGF-A and biosynthetically labeled with [35S]Cys/Met.
Precipitated VEGFs were separated by SDS–PAGE and
detected by using a PhosphoImager analyzer (Fujifilm).
Bioassay to monitor binding to the extracellular
domain of VEGFR-2
The bioassay has been described previously (Wise et
al., 1999). Briefly, purified proteins were tested for their
ability to induce proliferation of Ba/F3 cells that express
a chimeric receptor consisting of the extracellular do-
main of mouse VEGFR-2 and the transmembrane and
cytoplasmic domain of the mouse erythropoietin recep-
tor (EpoR). DNA synthesis of the cells was quantitated by
[3H]thymidine uptake and beta counting.
Mitogenesis assay with endothelial cells
The purified proteins were tested for mitogenic activity
on HMVECs. Cells grown in EGM-MV (Cambrex) contain-
ing 10% FCS and growth supplements, including epider-
mal growth factor and bovine brain extract as specified
by the manufacturer, were removed with trypsin, washed,
and aliquoted at 104 cells/well in a 24-well plate. Cells
were allowed to adhere for 6–16 h at 37°C before test or
control samples diluted in EGM-MV containing 2% FCS
but lacking the additional supplements were added. After
72 h of growth at 37°C cell proliferation was quantitated
by removing the cells with trypsin and counting cell
numbers with a hemocytometer (Wise et al., 1999).
Miles assay for vascular permeability
The Miles vascular permeability assay was performed
using guinea pigs as described previously (Wise et al.,
1999). In brief, anesthetized animals were given an intra-
cardiac injection of Evans blue dye. Purified proteins
were injected intradermally to shaved areas of the ani-
mal’s back. After 30 min the animal was sacrificed, the
skin was excised, and samples were eluted in form-
amide. The amount of dye extracted from the lesion was
determined by measuring OD 620 nm.
VEGF NOMENCLATURE
The ORFV-encoded VEGFs have been classified by
some researchers as VEGF-E in recognition of the
unique receptor binding profile of the viral factors as well
as the amino acid sequence divergence they show from
cellular VEGFs (Meyer et al., 1999; Ogawa et al., 1998). In
light of the extensive variations in amino acid sequence
seen between individual viral VEGFs, we believe that to
refer to a particular viral VEGF as VEGF-E may be mis-
leading. For example, the sequence identity between the
VEGFs encoded by ORFV strains NZ2 and NZ7 is no
greater than that between human VEGF-A and human
VEGF-B. To name the PCPV-encoded VEGF and both of
the ORFV-encoded VEGFs as VEGF-E would misrepre-
sent the sequence variation between them and suggest
a degree of shared function or origin that further inves-
tigations may not support. Such a nomenclature is likely
to give rise to confusion as further comparative analyses
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of these factors are published. We believe that it is
preferable to restrict the use of a single uppercase letter
suffix (VEGF-A, VEGF-B, etc.) to the classification of types
of cellular VEGF. We have therefore used the recom-
mended abbreviation of the virus name (van Regenmor-
tel et al., 2000) as a prefix and appended to it a strain
designation in subscript. This allows a distinction to be
made between the major variants of ORFV-encoded
VEGF (NZ2 and NZ7). In accordance with this nomencla-
ture, the vascular endothelial growth factor encoded
by Pseudocowpox virus strain VR634 is designated
PCPVVR634VEGF.
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